Literature DB >> 8163486

Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype.

L Bastien1, N Sawyer, R Grygorczyk, K M Metters, M Adam.   

Abstract

A cDNA clone encoding the human prostaglandin (PG) E2 receptor EP2 subtype has been isolated from a human lung cDNA library. The 1.9-kilobase pair cDNA, hEP2, encodes for a 488-amino acid protein with a predicted molecular mass of 53,115 and has the seven putative transmembrane domains characteristic of G protein-coupled receptors. The specific binding of [3H]PGE2 to COS cell membranes transfected with the hEP2 cDNA was of high affinity with an equilibrium dissociation constant (Kd) of 1 nM and the rank order of potency for prostaglandins in competition for [3H]PGE2 specific binding was PGE1 = PGE2 >> iloprost > PGF2 alpha > PGD2. In competition studies using more selective prostanoid-receptor agonist and antagonists, the [3H]PGE2 specific binding was competed by MB28767, an EP3 agonist, but not by the EP1-preferring antagonists AH6809 and SC19220, or by the EP2 agonist butaprost. Electrophysiological studies of Xenopus oocytes co-injected with hEP2 and cystic fibrosis transmembrane conductance regulator (cAMP-activated Cl- channel) cDNAs detected PGE2-specific inward Cl- currents, demonstrating that the hEP2 cDNA encoded a functional receptor which produced an increase in cAMP levels. Thus, we have cloned the human EP2 receptor subtype which is functionally coupled to increase in cAMP. Northern blot analysis showed that hEP2 is expressed as a 3.8-kilobase mRNA in a number of human tissues with the highest expression levels present in the small intestine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163486

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Identification of a region of the C-terminal domain involved in short-term desensitization of the prostaglandin EP4 receptor.

Authors:  M Bastepe; B Ashby
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

2.  Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway.

Authors:  Juanjuan Wu; Yushan Zhang; Nicole Frilot; Jae I Kim; Wan-Ju Kim; Yehia Daaka
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

Review 3.  Cyclooxygenase-2 in synaptic signaling.

Authors:  Hongwei Yang; Chu Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

4.  Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor.

Authors:  Hongwei Yang; Jian Zhang; Richard M Breyer; Chu Chen
Journal:  J Neurochem       Date:  2008-11-21       Impact factor: 5.372

Review 5.  Prostaglandin E2 receptor distribution and function in the gastrointestinal tract.

Authors:  I Dey; M Lejeune; K Chadee
Journal:  Br J Pharmacol       Date:  2006-10-02       Impact factor: 8.739

6.  Functional screening for G protein-coupled receptor targets of 14,15-epoxyeicosatrienoic acid.

Authors:  Xuehong Liu; Zu-Yuan Qian; Fuchun Xie; Wei Fan; Jonathan W Nelson; Xiangshu Xiao; Sanjiv Kaul; Anthony P Barnes; Nabil J Alkayed
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-09-17       Impact factor: 3.072

7.  Prostanoids and the cough reflex.

Authors:  Sarah A Maher; Maria G Belvisi
Journal:  Lung       Date:  2009-10-15       Impact factor: 2.584

8.  Characterization of the PGE2 receptor subtype in bovine chondrocytes in culture.

Authors:  A J de Brum-Fernandes; S Morisset; G Bkaily; C Patry
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

9.  Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery.

Authors:  S J Lydford; K C McKechnie; I G Dougall
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

Review 10.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.